The dream team
Name:
W. Scott Harkonen, MD
Position:
President, CEO and Founder
Experience:
Connetics, Univax Biologics
Name:
Tim Lynch
Position:
Chief Financial Officer
Experience:
Elan, Goldman Sachs
Name:
Peter Van Vlasselaer, PhD
Position:
Sr. VP, Technical Operations
Experience:
Dendreon, Stanford University
Name:
Nzeera Virani-Ketter, MD
Position:
VP, Clinical Research
Experience:
VaxGen, Gilead Sciences
Name:
Woodruff Emlen, MD
Position:
VP, Scientific Affairs
Experience:
Connetics, University of Colorado
Name:
Mary Fermi
Position:
Sr. Director, Commercial
Operations
Experience:
Syntex, 3M Diagnostic Systems
Biographies
W. Scott Harkonen, MD, is President and Chief
Executive Officer of InterMune Pharmaceuticals,
Inc. Prior to joining InterMune in 1998, Dr.
Harkonen served as Senior Vice President of
Product Development and Operations for
Connetics Corporation, where he was
instrumental in the spin-out of InterMune from
Connetics. From 1991 to 1995, he was the Vice
President of Medical and Regulatory Affairs at
Univax Biologics. Dr. Harkonen is well known
and respected by the investment community,
having played key roles in both the Univax and
Connetics public financings, including their IPOs.
Dr. Harkonen received an MD from the
University of Minnesota and holds an MBA from
the Haas School of Business at the University of
California, Berkeley.
Tim Lynch is Chief Financial Officer and Vice
President of Business Development at InterMune
Pharmaceuticals, Inc. Prior to joining InterMune
in 1999, Mr. Lynch served as Director of
Strategic Planning at Elan Corporation, plc. in
Dublin, Ireland. While at Elan, he managed
numerous corporate acquisitions and strategic
investments, as well as public and private
financings totaling over $1 billion. Also while at
Elan, he served as a pharmaceutical sales
representative in the San Francisco Bay Area.
Prior to Elan, Mr. Lynch worked in the
Investment Banking Division of Goldman, Sachs
& Co. and at Chase Securities, Inc. He is a
graduate of Harvard Business School and Colgate
University.
Peter Van Vlasselaer, PhD, is Senior Vice
President of Technical Operations at InterMune
Pharmaceuticals, Inc. Prior to joining InterMune
in 1999, Dr. Van Vlasselaer was the Vice
President of Development at Dendreon
Corporation, where he was in charge of product
development and manufacturing, and he
contributed to multiple regulatory filings with the
FDA. Previously he held positions at several
American as well as European scientific and
commercial institutions. Dr. Van Vlasselaer
received a PhD in immunology from the
University Leuven in Belgium and was an
immunology fellow at Stanford University.
Nzeera Virani-Ketter, MD, is Vice President of
Clinical Research at InterMune Pharmaceuticals,
Inc. Prior to joining InterMune, she was the
Senior Director of Clinical Research at VaxGen,
where she developed and executed two phase III
clinical trials in preventive vaccines for HIV
infection. Prior to that she was in clinical research
at Gilead Sciences, Chiron, the National Institutes
of Health at the Division of AIDS and Walter
Reed Army Institute of Research, working on
preventive and therapeutic vaccines as well as
immune-based therapies and combination
antiretroviral agents. She obtained her medical
degree at the University of Toronto, completed
her residency at a Stanford-affiliated hospital and
completed her fellowship in infectious diseases at
the Johns Hopkins University Hospital and the
University of California in San Francisco.
Woodruff Emlen, MD, is Vice President of
Scientific Affairs at InterMune Pharmaceuticals,
Inc. Prior to joining InterMune in 1998, Dr.
Emlen served as Vice President of Exploratory
Medicine at Connetics Corporation. From 1987
to 1997, he was a professor of medicine and
immunology at the University of Colorado Health
Sciences Center. From 1978 to 1986, Dr. Emlen
was a member of the medical faculty of the
University of Washington, Seattle. He has served
on scientific review committees for the National
Institutes of Health, the Veterans Administration
and the American College of Rheumatology. Dr.
Emlen is the author of more than 80 scientific
papers. He received an MD from the University of
California at San Diego and a BS from Stanford
University.
Mary Fermi is Senior Director of Commercial
Operations for InterMune Pharmaceuticals, Inc.
Prior to joining InterMune, she directed the
Managed Care Contracting Department at
Spectra Laboratories. Ms. Fermi completed
successful product launches for Syntex
Corporation and 3M Diagnostic Systems. From
1991 to 1995, Ms. Fermi worked with Igenex,
Inc., a start-up biotechnology-based diagnostics
company. She received a BA in microbiology
from San Francisco State University and an MBA
from San Jose State University. |
